New pill nearly doubles survival time for pancreatic cancer patients
In a randomized study of 500 patients, the daily pill cut severe side effects and raised median survival to 13.2 months from 6.7 months.
- Researchers reported Sunday that an experimental pill nearly doubled survival times for patients with advanced pancreatic cancer, achieving a median of 13.2 months compared to 6.7 months for chemotherapy in a 500-patient study.
- Pancreatic cancer remains one of the deadliest forms, with a five-year overall survival rate of 13%, because so-called KRAS mutations were long considered undruggable due to difficulty binding to mutated proteins.
- Former U.S. Sen. Ben Sasse described on 60 Minutes how he experienced less pain taking the drug, which uses molecular glue to bind with KRAS subtypes, though patients reported severe rashes and mouth sores.
- Maker Revolution Medicines funded the study, and the Food and Drug Administration plans to expedite review of the drug while allowing expanded access to patients who meet certain criteria.
- Brian Wolpin, director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, said the drug should become a new standard of care while researchers explore whether tumor shrinkage might let patients qualify for surgery.
14 Articles
14 Articles
Breakthrough pancreatic cancer treatment could double survival time
A new study on a groundbreaking pancreatic cancer drug finds that it has the potential to double survival rates for more than 90 percent of patients. Researchers are now exploring whether the drug, called daraxonrasib, could also be effective in lung, ovarian, and colorectal cancers. NBC News’ Erika Edwards reports.
Daraxonrasib significantly extends survival in metastatic pancreatic cancer
At the ASCO annual meeting, Dana-Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic cancer, regardless of RAS mutation status, taking daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor, compared with chemotherapy.
Pancreatic cancer has been, for decades, an untouchable tumor. The most lethal. Intractable. With a five-year survival of less than 10% and an extremely limited therapeutic arsenal, the diagnosis of this tumor, almost always in very advanced stages, almost always gave rise to a devastating, dead-end panorama. But the turns have begun to turn: the disease remains extremely aggressive and deadly, but a new targeted therapy has just achieved unprec…
Coverage Details
Bias Distribution
- 62% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
